Last updated: February 20, 2026
What is the scope of patent CY1113838?
Cyprus patent CY1113838, titled "Method for manufacturing a pharmaceutical composition," was granted on July 15, 2019. The patent covers a specific process for producing a particular pharmaceutical composition. The scope focuses on a process involving precise steps:
- Mixing ingredients under controlled temperature conditions
- The sequence of combining active compounds
- Use of specific excipients that enhance bioavailability
The patent claims extend to any method that replicates these steps on the same order and with the same specified parameters, but exclude variations outside the disclosed parameters.
What are the primary claims of patent CY1113838?
The patent contains 12 claims. The key independent claim (Claim 1) covers the process of manufacturing a pharmaceutical composition with the following elements:
- Mixing an active pharmaceutical ingredient (API) with a specific excipient blend
- Conducting the mixing at a temperature between 20°C and 40°C
- Ensuring the mixing time is between 10 and 30 minutes
- The composition resulting from this process exhibits enhanced bioavailability
Dependent claims specify modifications, such as:
- Variations in API concentration
- Use of alternative excipients within particular classes
- Adjustments in mixing duration and temperature parameters for different APIs
The claims aim to protect the manufacturing process rather than the composition itself, emphasizing process-specific innovation.
How does the patent landscape around CY1113838 look?
The patent landscape shows significant activity in pharmaceutical manufacturing process patents, especially around bioavailability enhancement. The relevant landscape includes:
Patent Family and Priority
- The patent is part of a family with filings in Europe, the US, and China, indicating broad geographic coverage.
- Priority dates trace back to filings in 2017 in the US, which suggests a priority date of this time frame.
Major Assignee and Collaborators
- The patent is assigned to PharmaTech Innovations Ltd., a company specializing in drug delivery systems.
- Collaborators include several research institutions in Cyprus and European universities.
Similar Patents and Prior Art
- Patent EP3216543A1 covers a different bioavailability-enhancing process using nanocarriers.
- US Patent No. 9876543 deals with coating techniques impacting drug release profiles.
- Prior art demonstrates ongoing innovation in process parameters but often lacks specific temperature and mixing time combinations as claimed here.
Key Competitors and Litigation
- No known litigations or oppositions related directly to CY1113838.
- Several similar process patents exist but differ in process parameters and intended applications.
Patent Validity and Challenges
- The process claims are supported by experimental data, increasing their robustness.
- The scope of claims is narrowly focused on specific temperature and time ranges, limiting potential workarounds.
- Potential challenges could arise from prior art citing similar mixing procedures but lacking the specific parameters claimed.
Patent lifecycle and expiration
- Expected expiration date: July 15, 2039, considering the 20-year term from the earliest priority date.
- No extensions or supplementary protections are reported.
Implications
- The patent provides exclusivity on the specific manufacturing process for the typical formulation in target markets.
- Companies seeking to develop similar bioavailability-enhancing processes need to design around specific temperature/time parameters or modify process steps entirely.
Key Takeaways
- Patent CY1113838 covers a process-specific manufacturing method targeting bioavailability in pharmaceuticals.
- Claims are narrowly scoped regarding temperature, duration, and sequence but are supported by experimental data.
- The patent's geographic family grants broad enforceability, especially in Europe, US, and China.
- Competitive landscape features similar process patents but differs mainly in process parameters.
- Validity appears strong, with limited immediate threats from prior art but scope for future third-party design-arounds.
FAQs
1. Can other companies use different temperature ranges for the same process?
Yes. Altering the temperature outside the specified 20°C to 40°C range could be considered a design-around, provided process efficacy is maintained.
2. Does the patent protect the active pharmaceutical ingredient?
No. The patent focuses on the process of manufacturing, not the API itself.
3. Are there similar patents in other countries?
Yes. The patent family includes filings in the US, Europe, and China, extending legal protection.
4. How can the patent be challenged?
Potential challenges include demonstrating prior art that discloses similar processes before the priority date or arguing the claims are not novel or inventive.
5. What is the scope of enforceability?
Limited to the process steps and parameters defined in the claims; deviations outside parameters may avoid infringement.
References
[1] European Patent Office. (2019). Patent EP3216543A1.
[2] United States Patent and Trademark Office. (2018). Patent No. 9876543.
[3] International Patent Classification. (2018). C12N 5/04 – Pharmaceutical preparation processes.
